The Journal of Neuroscience, February 25, 2009, 29(8):2312-2321; doi:10.1523/JNEUROSCI.2168-08.2009
Previous Article | Next Article 
Neurobiology of Disease
Congenital Hypomyelinating Neuropathy with Lethal Conduction Failure in Mice Carrying the Egr2 I268N Mutation
Robert H. Baloh,1,3
Amy Strickland,2
Elizabeth Ryu,2
Nam Le,2
Timothy Fahrner,2
Mao Yang,2
Rakesh Nagarajan,2 and
Jeffrey Milbrandt1,2,3
Departments of 1Neurology and 2Pathology, and 3Hope Center for Neurological Diseases, Washington University School of Medicine, St. Louis, Missouri 63110
Correspondence should be addressed to either of the following: Dr. Robert H. Baloh, Department of Neurology, Washington University School of Medicine, P.O. Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110, Email: rbaloh{at}wustl.edu; or Dr. Jeffrey Milbrandt, Department of Pathology, Washington University School of Medicine, P.O. Box 8118, 660 South Euclid Avenue, St. Louis, MO 63110, Email: jeff{at}pathology.wustl.edu
Mouse models of human disease are helpful for understanding the pathogenesis of the disorder and ultimately for testing potential therapeutic agents. Here, we describe the engineering and characterization of a mouse carrying the I268N mutation in Egr2, observed in patients with recessively inherited Charcot–Marie–Tooth (CMT) disease type 4E, which is predicted to alter the ability of Egr2 to interact with the Nab transcriptional coregulatory proteins. Mice homozygous for Egr2I268N develop a congenital hypomyelinating neuropathy similar to their human counterparts. Egr2I268N is expressed at normal levels in developing nerve but is unable to interact with Nab proteins or to properly activate transcription of target genes critical for proper peripheral myelin development. Interestingly, Egr2I268N/I268N mutant mice maintain normal weight and have only mild tremor until 2 weeks after birth, at which point they rapidly develop worsening weakness and uniformly die within several days. Nerve electrophysiology revealed conduction block, and neuromuscular junctions showed marked terminal sprouting similar to that seen in animals with pharmacologically induced blockade of action potentials or neuromuscular transmission. These studies describe a unique animal model of CMT, whereby weakness is due to conduction block or neuromuscular junction failure rather than secondary axon loss and demonstrate that the Egr2–Nab complex is critical for proper peripheral nerve myelination.
Key words: myelin; peripheral nerve; axon; neuromuscular junction; nerve; neuropathy
Received May 13, 2008;
revised Dec. 29, 2008;
accepted Jan. 11, 2009.
Correspondence should be addressed to either of the following: Dr. Robert H. Baloh, Department of Neurology, Washington University School of Medicine, P.O. Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110, Email: rbaloh{at}wustl.edu; or Dr. Jeffrey Milbrandt, Department of Pathology, Washington University School of Medicine, P.O. Box 8118, 660 South Euclid Avenue, St. Louis, MO 63110, Email: jeff{at}pathology.wustl.edu
Related articles in J. Neurosci.:
- This Week in The Journal
J. Neurosci. 2009 29: i.
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
E. Arnaud, J. Zenker, A.-S. de Preux Charles, C. Stendel, A. Roos, J.-J. Medard, N. Tricaud, J. Weis, U. Suter, J. Senderek, et al.
SH3TC2/KIAA1985 protein is required for proper myelination and the integrity of the node of Ranvier in the peripheral nervous system
PNAS,
October 13, 2009;
106(41):
17528 - 17533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Sasaki, B. P. S. Vohra, R. H. Baloh, and J. Milbrandt
Transgenic Mice Expressing the Nmnat1 Protein Manifest Robust Delay in Axonal Degeneration In Vivo
J. Neurosci.,
May 20, 2009;
29(20):
6526 - 6534.
[Abstract]
[Full Text]
[PDF]
|
 |
|